论文部分内容阅读
目的探讨抗栓酶对不稳定型心绞痛的疗效及其对血小板膜糖蛋白CD_(62)P表达和血黏度的影响。方法 82例冠心病不稳定型心绞痛患者随机分成抗栓酶组和对照组。抗栓酶组在常规抗心绞痛治疗基础上静脉点滴抗栓酶5BU连续5d,对照组加用低分子肝素0.4ml1次/12h皮下注射连续5d。观察两组用药前后的实验室指标及疗效。结果用药后,抗栓酶组的心绞痛严重程度减轻,较对照组明显(P<0.05),CD_(62)P活性[(3.61%±1.21%)比(4.08%±1.06%)]、纤维蛋白原[(2.91±0.71)g/L比(3.71±0.90)g/L]及血浆黏度[(1.05±0.14)cp比(1.61±0.19)cp]明显低于对照组(P均<0.01),治疗中无出血等不良反应。结论抗栓酶能显著减轻心绞痛严重程度,降低CD_(62)P活性和纤维蛋白原及血浆黏度。
Objective To investigate the curative effect of antithrombin on unstable angina pectoris and its effect on platelet membrane glycoprotein CD62p expression and blood viscosity. Methods 82 cases of coronary heart disease patients with unstable angina were randomly divided into antithrombotic group and control group. In the antithrombin group, intravenous antithrombotic enzyme 5BU was given for 5 consecutive days on the basis of conventional anti-angina treatment, and the control group was subcutaneously injected with 0.4ml of low molecular weight heparin once / 12h for 5 days continuously. Observed before and after the two groups of laboratory indicators and efficacy. Results After treatment, the severity of angina in the antithrombotic group was significantly lower than that in the control group (P <0.05), and the activity of CD_ (62) P [(3.61% ± 1.21%) vs (4.08% ± 1.06% (2.91 ± 0.71) g / L (3.71 ± 0.90) g / L and plasma viscosity (1.05 ± 0.14) cp (1.61 ± 0.19) cp were significantly lower than those in the control group (all P <0.01) No bleeding and other adverse reactions in the treatment. Conclusion Antithrombotic enzyme can significantly reduce the severity of angina pectoris and decrease the activity of CD_ (62) P and the fibrinogen and plasma viscosity.